Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113117
Chunk: 75

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 75
---
, for the purchase and sale of (i) 15,000 shares of common
stock, (ii) 112,500 February 2025 Pre-funded Warrants; and (iii) common warrants to purchase up to 127,551 shares of common stock (the
“February 2025 Common Warrants”), at a combined public offering price of $39.20 per share and Warrant (See Note 8).

The following table summarizes
the pre-funded warrants and February 2025 Common Warrants sold to our related party:

| Purchasers                                           |     | Pre-Funded 
 Warrants   
 Purchased  |        |     | Total    
 Purchase 
 Price    |         |     | February 2025 
 Common        
 Warrants      
 Issued        |        |
|:-----------------------------------------------------|:----|:-----------|-------:|:----|:---------|--------:|:----|:--------------|-------:|
| Atwood-Edminster Trust dtd 4-2-2000 and GVN, LLC (2) |     |            | 25,510 |     | $        | 999,992 |     |               | 25,510 |

| (1) | Daniel Corey served as the Chief Technology Officer and a member of the board of directors of the Company from February 2024 to September 2024, and previously served as Chief Executive Officer, Chief Scientific Officer, and a member of the board of directors of Legacy CERo until the closing of the Business Combination in February 2024. |

| (2) | Brian G. Atwood served as Chairman and Chief Executive Officer of the Company from February 2024 to September 2024, and previously served as Chairman of PBAX until the closing of the Business Combination in February 2024. Mr. Atwood is currently a member of the board of directors of the Company and serves as a trustee of Atwood-Edminster Trust dtd 4-2-2000. GVN, LLC, is a limited liability company of which the sole member is the Atwood-Edminster Trust dtd 4-2-2000, and of which Brian G. Atwood and Lynne H. Edminster are the managers. |

| (3) | Chris Ehrlich has served as the Chairman and Chief Executive Officer of the Company since December 2024, and previously served as (i) interim Chairman and Chief Executive Officer of the Company from October 2024 to November